
Washburn Therapeutics Inc Profile last edited on: 7/17/14
CAGE: 4TSV1
UEI:
Business Identifier: Development of biologically active gels controlling inflammation by selectively neutralizing pro-inflammatory cytokines based on a technology being licensed exclusively by the company. Preliminary results of these gels have demonstrated that conjugates of antibodies against tumor necrosis factor-alpha and hyaluronic acid were able to reduce secondary necrosis in a partial-thickness rat burn model by 70% This technology could mean the possible prevention of burn progression through local control of inflammatory responses and overall improvement of healing outcomes. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
6743 Wilkins Avenue
Pittsburgh, PA 15217
Pittsburgh, PA 15217
(412) 908-1309 |
newell@washburntherapeutics.com |
www.washburntherapeutics.com |
Location: Single
Congr. District: 18
County: Allegheny
Congr. District: 18
County: Allegheny
Public Profile
Washburn Therapeutics, Inc. is developing a new class of polymer therapeutics to treat a broad range of inflammatory conditions. Polymer therapeutics is an emerging class of drug that conjugates a known therapeutic agent to a polymer in order to provide targeted delivery. The technology was developed from Carnegie Mellon University and has been licensed exclusively by the firm.
Polymer therapeutics work by using a polymer conjugation in order to localize the effects of antibody inhibitors of tumor necrosis factor- a protein known as the central mediator of inflammation. These antibodies form the basis for a $13 Billion Dollar sector of the biotechnology industry and significant safety concerns have been raised because of their powerful immunosuppressive effects. By localizing the delivery of TNF-ainhibitors, it may be possible to treat psoriasis, burns, chronic wounds, and other conditions characterized by intense, local inflammation without many of the side-effects observed through standard administering of the unconjugated drug.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2013 | 1 | DHA | $150,000 | |
Project Title: Reduction of Burn Progression and Scar Contracture with Cytokine-Neutralizing Gels | ||||
2010 | 1 | NIH | $185,770 | |
Project Title: Development Of Cytokine-Inhibiting Gels For Treating Chronic Wounds |
Key People / Management
Newell R Washburn -- President
Company News
There are no news available.